Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type
Brief Summary: The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.


Options:
A: Inclusion Criteria

You may be eligible for this study if you:

* Are HIV positive.
* Have been diagnosed with AIDS dementia complex (ADC).
* Have an estimated IQ of at least 70 (before the onset of ADC) or the ability to read at a 6th grade level.
* Have impaired mental skills.
* Are age18 or older.

Exclusion Criteria

You will not be eligible for this study if you:

* Have a history of a neurologic disease unrelated to HIV infection.
* Have a history of chronic seizures or head injuries.
* Have a history of central nervous system infections.
* Have certain cancers.
* Have any psychiatric illness.
* Have an active AIDS-defining opportunistic infection.
* Are pregnant or breast-feeding.
B: Inclusion Criteria:

* Parkinson's disease of more than 5 years
* Subthalamic nucleus stimulation
* Gait disorders impeding moderately to severely the activities of daily living
* gait disorders including freezing of gait
* able to walk without physical assistance

Exclusion Criteria:

* Dementia (MMSE \< 27 et score de Mattis \< 130)
* Requiring dopatherapy modification
* Requiring subthalamic stimulation parameters adaptation
* Psychiatric disorders: hallucinations, unstable thymic disorders, psychosis)
* Cardiac disorders: dysrhythmia or unstable arterial hypertension
* Unstable or severe medical illness
* intolerance or contraindication to memantine
C: Inclusion Criteria:

1. A diagnosis of multiple sclerosis as defined by the McDonald criteria. Patients with relapsing-remitting, secondary progressive, and primary progressive forms of MS are eligible.
2. Age between 18 and 65 years.
3. Demonstrated cognitive dysfunction at screening defined as a score worse than 1.0 standard deviations below the mean on the PASAT or the CVLT-II.

Exclusion Criteria:

1. A history of major depression, psychosis, or a score \> 19 on the Beck's Depression Inventory.
2. Corrected binocular visual acuity worse than 20/50; any impairment of binocular color vision.
3. Patients that do not speak English as a primary language (fluency may impact performance).
4. A clinically significant MS exacerbation within 30 days of the screening
5. Pregnancy
6. Renal insufficiency.
7. History of seizures.
8. Patients using acetazolamide (Diamox, Ak-sol, Storzolamide), dichlorphenamide (Daranide), methazolamide (Neptazane) or topiramate (Topamax), dextromethorphan (Robitussin DM and other cold remedies), or amantadine (Symmetrel).
9. Use of medical marijuana in the prior six months.
10. History of alcohol abuse or illicit drug use in the prior six months.
D: Inclusion Criteria:

Outpatients who:

* had a primary diagnosis of probable Alzheimer's Disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) criteria, and with Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revised (DSM IV TR) criteria for dementia of the Alzheimer's type
* had moderate to severe dementia, defined as a Mini Mental State Examination (MMSE) total score \>=5 and \<=15 at screening. Before substantial protocol amendment SA04 (dated 7 October 2004) was implemented, the MMSE total score range at screening was \>=8 and \<=18. Substantial protocol amendment SA07 (dated 4 September 2009) allowed patients who had previously had an MMSE score of 16 or 17 to be re-screened \>6 months after their initial screening and, if there was documented evidence of cognitive decline, to be enrolled in the study
* had a Neuropsychiatric Inventory (NPI) total score \>=13 and an NPI agitation/aggression subitem score \>=1 at screening and baseline
* did not have vascular dementia or a modified Hachinski Ischaemia Scale score \>4 at screening

Exclusion Criteria:

* Evidence of clinically significant active disease, evidence of other neurological disorders, and previous treatment with memantine

Answer: D